Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) – Research analysts at Zacks Small Cap upped their FY2025 earnings estimates for Azitra in a report released on Tuesday, November 18th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn ($2.67) per share for the year, up from their prior estimate of ($3.41). The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share. Zacks Small Cap also issued estimates for Azitra’s Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.88) EPS.
Separately, Maxim Group dropped their target price on Azitra from $13.32 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $4.00.
Azitra Stock Down 3.9%
AZTR opened at $0.33 on Thursday. The company has a fifty day moving average of $0.62 and a two-hundred day moving average of $1.19. Azitra has a fifty-two week low of $0.31 and a fifty-two week high of $4.33.
Institutional Trading of Azitra
A hedge fund recently raised its stake in Azitra stock. National Bank of Canada FI raised its position in Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) by 175.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 110,000 shares of the company’s stock after buying an additional 70,000 shares during the period. National Bank of Canada FI owned about 0.88% of Azitra worth $34,000 at the end of the most recent reporting period. 11.16% of the stock is currently owned by institutional investors.
About Azitra
Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
Recommended Stories
- Five stocks we like better than Azitra
- What is the Nasdaq? Complete Overview with History
- Applied Materials: Up 40% in 2025 With Room to Run Long-Term
- What is a Low P/E Ratio and What Does it Tell Investors?
- onsemi Places a $6 Billion Bet on Its Own Stock
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
